Subcutaneous or oral administration of rhIL-11 modulated the contact hypersensitivity response.
Recombinant human interleukin 11 (rhIL-11) is a multifunctional cytokine with immunomodulatory activity on both T cells and macrophages. The effects of rhIL-11 in a murine model of contact hypersensitivity (CHS) response have been studied. The CHS response is a T cell-mediated response directed against chemically modified self-proteins following epidermal exposure to haptens. CHS is generated in two phases. The sensitization phase involves dermal dendritic cell recognition of haptenized proteins and antigen presentation. The effector phase involves T cell recognition and activation. In mice sensitized with oxazolone, CHS was induced by secondary challenge to the right ear and measured by ear swelling 24 h later. rhIL-11 significantly suppressed CHS as measured by ear swelling and tissue myeloperoxidase activity when injected subcutaneously for 5 days from the day of sensitization or when administered only on the day before and the day of challenge, but was not effective when administered prior to or on the day of sensitization. These results indicate that subcutaneously administered rhIL-11 may modulate the effector phase of CHS. Administration of rhIL-11 as an oral gavage prior to sensitization also reduced CHS. However oral administration of rhIL-11 after sensitization had no effect. These results suggest that orally and subcutaneously administered rhIL-11 may act through different mechanisms to affect CHS.
Peterson
R L
RL
Department of Molecular Medicine and Pharmacogenomics, Genetics Institute Inc., Andover, MA, 01810, USA.
Wang
L L
LL
Albert
L
L
Dorner
A J
AJ
D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D001706:Biopsy; D003713:Dendritic Cells / Q000378:metabolism; D003877:Dermatitis, Contact / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004487:Edema / Q000378:metabolism; D004817:Epidermis / Q000187:drug effects; D005260:Female; D006801:Humans; D006965:Hyperplasia / Q000378:metabolism; D007279:Injections, Subcutaneous; D017370:Interleukin-11 / Q000008:administration & dosage* / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000096:biosynthesis; D051379:Mice; D008807:Mice, Inbred BALB C; D009195:Peroxidase / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D011994:Recombinant Proteins / Q000008:administration & dosage* / Q000627:therapeutic use*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013601:T-Lymphocytes / Q000378:metabolism; D013997:Time Factors
D000970:Antineoplastic Agents; D017370:Interleukin-11; D007376:Interleukin-2; D012333:RNA, Messenger; D011994:Recombinant Proteins; D009195:Peroxidase; C105308:oprelvekin